Literature DB >> 30270203

Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack.

Richard F Schlenk1,2, Sonia Jaramillo2, Carsten Müller-Tidow2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30270203      PMCID： PMC6165816          DOI： 10.3324/haematol.2018.200485

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Learning from a Trial Stopped by a Data and Safety Monitoring Board.

Authors:  David Harrington; Jeffrey M Drazen
Journal:  N Engl J Med       Date:  2018-05-24       Impact factor: 91.245

Review 2.  What's new in consolidation therapy in AML?

Authors:  Richard F Schlenk; Sonia Jaramillo; Carsten Müller-Tidow
Journal:  Semin Hematol       Date:  2018-08-29       Impact factor: 3.851

Review 3.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

Review 4.  Relapsed/refractory acute myeloid leukemia: any progress?

Authors:  Richard F Schlenk; Carsten Müller-Tidow; Axel Benner; Meinhard Kieser
Journal:  Curr Opin Oncol       Date:  2017-11       Impact factor: 3.645

5.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

6.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

7.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

8.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245

9.  Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.

Authors:  Alan K Burnett; Emma Das Gupta; Steve Knapper; Asim Khwaja; Marion Sweeney; Lars Kjeldsen; Timothy Hawkins; Sophie E Betteridge; Paul Cahalin; Richard E Clark; Robert K Hills; Nigel H Russell
Journal:  Haematologica       Date:  2018-07-05       Impact factor: 9.941

Review 10.  Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.

Authors:  M D Kaymakcalan; Y Je; G Sonpavde; M Galsky; P L Nguyen; D Y C Heng; C J Richards; T K Choueiri
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640
View more
  1 in total

1.  Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics.

Authors:  Xavier Roussel; Etienne Daguindau; Ana Berceanu; Yohan Desbrosses; Walid Warda; Mathieu Neto da Rocha; Rim Trad; Eric Deconinck; Marina Deschamps; Christophe Ferrand
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.